KR100518986B1 - 아플리딘을 사용하여 암을 치료하는 방법 - Google Patents

아플리딘을 사용하여 암을 치료하는 방법 Download PDF

Info

Publication number
KR100518986B1
KR100518986B1 KR10-2002-7006155A KR20027006155A KR100518986B1 KR 100518986 B1 KR100518986 B1 KR 100518986B1 KR 20027006155 A KR20027006155 A KR 20027006155A KR 100518986 B1 KR100518986 B1 KR 100518986B1
Authority
KR
South Korea
Prior art keywords
aplidine
drugs
patients
hours
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2002-7006155A
Other languages
English (en)
Korean (ko)
Other versions
KR20020064313A (ko
Inventor
그린 토마스 페어클로스
크리스 트웰브스
루이스 파즈-아레스
Original Assignee
파르마 마르, 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed by 파르마 마르, 에스.에이. filed Critical 파르마 마르, 에스.에이.
Publication of KR20020064313A publication Critical patent/KR20020064313A/ko
Application granted granted Critical
Publication of KR100518986B1 publication Critical patent/KR100518986B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
KR10-2002-7006155A 1999-11-15 2000-11-15 아플리딘을 사용하여 암을 치료하는 방법 Expired - Fee Related KR100518986B1 (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB9927006.8 1999-11-15
GB0005701.8 2000-03-09
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0007639.8 2000-03-29
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0015496.3 2000-06-23
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
GB0025209.8 2000-10-13

Publications (2)

Publication Number Publication Date
KR20020064313A KR20020064313A (ko) 2002-08-07
KR100518986B1 true KR100518986B1 (ko) 2005-10-06

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2002-7006155A Expired - Fee Related KR100518986B1 (ko) 1999-11-15 2000-11-15 아플리딘을 사용하여 암을 치료하는 방법

Country Status (27)

Country Link
US (1) US20090298752A1 (https=)
EP (1) EP1229922B1 (https=)
JP (1) JP2003514025A (https=)
KR (1) KR100518986B1 (https=)
CN (1) CN1423564A (https=)
AT (1) ATE363910T1 (https=)
AU (1) AU780417B2 (https=)
BG (1) BG65381B1 (https=)
BR (1) BR0015811A (https=)
CA (1) CA2391502A1 (https=)
CY (1) CY1106825T1 (https=)
CZ (1) CZ302498B6 (https=)
DE (1) DE60035120T2 (https=)
DK (1) DK1229922T3 (https=)
ES (1) ES2288486T3 (https=)
HK (1) HK1045648B (https=)
HU (1) HUP0203906A2 (https=)
IL (1) IL149488A0 (https=)
MX (1) MXPA02004862A (https=)
NO (1) NO330719B1 (https=)
NZ (1) NZ518847A (https=)
PL (1) PL200922B1 (https=)
PT (1) PT1229922E (https=)
RU (1) RU2261104C2 (https=)
SI (1) SI1229922T1 (https=)
SK (1) SK287762B6 (https=)
WO (1) WO2001035974A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CZ2003993A3 (cs) 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
WO2004080421A2 (en) * 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
ATE406171T1 (de) * 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
CN101389347B (zh) * 2006-02-28 2013-03-27 法马马有限公司 提高的抗肿瘤治疗
JP5547487B2 (ja) * 2006-11-03 2014-07-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗癌化合物の投与方法
RU2360712C1 (ru) * 2007-10-02 2009-07-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения местно-распространенного неоперабельного рака прямой кишки
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
US20110009335A1 (en) * 2008-03-07 2011-01-13 Pharma Mar, S.A. Anticancer Treatments
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
ATE74761T1 (de) * 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
EP0981352B8 (en) * 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
ES2272462T3 (es) * 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
MXPA03002479A (es) * 2000-10-05 2004-05-24 Immunex Corp Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
CZ2003993A3 (cs) * 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
ATE406171T1 (de) * 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
WO2004080421A2 (en) * 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
CA2519234A1 (en) * 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CN101389347B (zh) * 2006-02-28 2013-03-27 法马马有限公司 提高的抗肿瘤治疗
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
CN1423564A (zh) 2003-06-11
CA2391502A1 (en) 2001-05-25
AU1402301A (en) 2001-05-30
BG65381B1 (bg) 2008-05-30
PL355335A1 (en) 2004-04-19
NO330719B1 (no) 2011-06-20
MXPA02004862A (es) 2003-01-28
US20090298752A1 (en) 2009-12-03
ATE363910T1 (de) 2007-06-15
NO20022293D0 (no) 2002-05-14
CZ302498B6 (cs) 2011-06-15
ES2288486T3 (es) 2008-01-16
PL200922B1 (pl) 2009-02-27
BR0015811A (pt) 2002-08-06
PT1229922E (pt) 2007-09-12
AU780417B2 (en) 2005-03-17
BG106714A (en) 2003-02-28
CZ20021697A3 (cs) 2003-02-12
HK1045648B (en) 2007-09-21
NO20022293L (no) 2002-07-05
NZ518847A (en) 2004-02-27
RU2002115864A (ru) 2004-01-20
SK287762B6 (sk) 2011-09-05
HK1045648A1 (en) 2002-12-06
WO2001035974A3 (en) 2001-11-01
SK6592002A3 (en) 2003-08-05
JP2003514025A (ja) 2003-04-15
KR20020064313A (ko) 2002-08-07
DE60035120D1 (de) 2007-07-19
EP1229922B1 (en) 2007-06-06
EP1229922A2 (en) 2002-08-14
RU2261104C2 (ru) 2005-09-27
SI1229922T1 (sl) 2008-04-30
IL149488A0 (en) 2002-11-10
DE60035120T2 (de) 2008-01-31
DK1229922T3 (da) 2007-10-08
WO2001035974A2 (en) 2001-05-25
HUP0203906A2 (en) 2003-03-28
CY1106825T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
US20090298752A1 (en) Aplidine treatment of cancers
JP5777562B2 (ja) ガンを治療するための組成物とｅｔ７４３の使用
Tourneau et al. Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison
JP2004512370A (ja) カハラリドｆ
JP2004512370A5 (https=)
AU2002336206B2 (en) Use of aplidine for the treatment of pancreatic cancer
US7507766B2 (en) Treatment of cancers
EP1330254B1 (en) Treatment of cancers by aplidine in conjunction with carnitine or acetylcarnitine
AU2001294024A1 (en) Treatment of cancers by aplidine in conjunction with a myoprotector
US20120077755A1 (en) Compounds For, and Methods of, Treating Cancer and Inhibiting Invasion and Metastases
ZA200302738B (en) Treatment of cancers by aplidine in conjuction with a myoprotector.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20110907

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120928

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120928